Skip to search formSkip to main contentSkip to account menu

RPL 554

Known as: RPL-554, RPL554 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle
  • 2017
  • Corpus ID: 62804213
6,794,391 B2* 9/2004 Oxford ................ CO7D 471,04 (71) Applicant: VERONA PHARMA PLC, Cardiff 514,211.12 (GB) 7,105,663 B2… 
2016
2016
RPL554, an inhaled PDE3/4 inhibitor, causes profound and sustained bronchodilation in healthy volunteers and COPD patients
RPL554 has previously been shown to be a well tolerated bronchodilator, bronchoprotective, & anti-inflammatory agent in clinical… 
2016
2016
LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD…
RPL554 is a novel, well tolerated dual PDE3/4 inhibitor with significant bronchodilator activity in COPD & asthma together with… 
2016
2016
RPL554, an inhaled PDE3/4 inhibitor, causes comparable bronchodilation to high dose nebulised salbutamol in asthmatics with fewer systemic effects
RPL554 has bronchodilator, bronchoprotective, & anti-inflammatory effects. We investigated the dose-ranging effects & safety of a…